LEXINGTON, Mass.--(BUSINESS WIRE)--March 9, 2006--Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today announced that the U.S. Food and Drug Administration (“FDA”) has accepted the Company’s Investigational New Drug (“IND”) application for NEBIDO, its long-acting injectable testosterone preparation for the treatment of male hypogonadism. The Company intends to begin its pharmacokinetic study by the end of March.
